Odyssey Therapeutics to present OD-001 ulcerative colitis data at UEG Week
Tweet Send to a Friend
Odyssey Therapeutics, Inc. (Nasdaq: ODTX) announced that additional Phase 2a induction data for its drug candidate OD-001 in moderate to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




